X

Medline.com Mobile Ordering

Product search and ordering for your mobile devices.

Opticell Ag+ Gelling Fiber with Silver
 
Click to enlarge. To view full image, click here
 

Opticell Ag+ Gelling Fiber with Silver

  • Click here to access the available clinical content for Opticell Ag+ Gelling Fiber Wound Dressing
  • Opticell® Ag+ wound dressing uses a unique gelling ChytoformTM technology that allows the absorbent fibers of the dressing to transform into a clear and conformable gel.
  • The unique gelling action helps manage drainage and remove dead, damaged and infected tissue from the wound, trapping it for later removal at the dressing change.
  • ChytoformTM technology wicks fluid only vertically, not laterally, helping to prevent maceration.
  • Opticell Ag+ has a conformable and thin profile that provides optimal contact with the wound.
  • Although Opticell is designed specifically for moderate to heavily draining wounds, it can also be pre-moistened for effective use on dry or lightly draining wounds.
  • Opticell Ag+ delivers broad spectrum antimicrobial efficacy. The dressings contain 0.75% ionic silver by weight. When the dressing encounters a wound environment, silver ions are activated to manage bioburden. The silver inhibits the growth of bacteria and fungi, yet is completely harmless to skin cells (noncytotoxic).1
  • Indications: Partial- and full-thickness wounds; 1st- and 2nd-degree burns; Diabetic foot ulcers; Venous stasis ulcers; Arterial ulcers and leg ulcers of mixed etiology; pressure injuries; Surgical wounds; Donor sites

    1. In-vitro antibacterial data on file
 
 
 

ORDERING INFORMATION

To view pricing/availability

Login
Material Description Packaging
MSC9818EP DRESSING, GEL FIBER, OPTICELL AG+, .75X18 50/CS
MSC9818EPH DRESSING, GEL FIBER, OPTICELL AG+, .75X18 1 EA
MSC9818EPZ DRESSING, GEL FIBER, OPTICELL AG+, .75X18 5/BX
MSC9822EP DRESSING, GEL FIBER, OPTICELL AG+,2X2 100/CS
MSC9822EPH DRESSING, GEL FIBER, OPTICELL AG+,2X2 1 EA
MSC9822EPZ DRESSING, GEL FIBER, OPTICELL AG+,2X2 10/BX
MSC9845EP DRESSING, GEL FIBER, OPTICELL AG+,4X5 50/CS
MSC9845EPH DRESSING, GEL FIBER, OPTICELL AG+,4X5 1 EA
MSC9845EPZ DRESSING, GEL FIBER, OPTICELL AG+,4X5 10/BX
MSC9866EP DRESSING, GEL FIBER, OPTICELL AG+, 6X6 50/CS
MSC9866EPH DRESSING, GEL FIBER, OPTICELL AG+, 6X6 1 EA
MSC9866EPZ DRESSING, GEL FIBER, OPTICELL AG+, 6X6 5/BX
MSC98812EP DRESSING, GEL FIBER, OPTICELL AG+,8 X 12 50/CS
MSC98812EPH DRESSING, GEL FIBER, OPTICELL AG+,8 X 12 1 EA
MSC98812EPZ DRESSING, GEL FIBER, OPTICELL AG+,8 X 12 5/BX
 

MORE ABOUT THIS ITEM

 

Exclusive Gelling Technology Provides Powerful Yet Gentle Moisture Management

Chytoform™ Chitosan-based Gelling Technology

Opticell with Chytoform technology is the next generation of chronic wound care dressings.

Chytoform gelling fiber is primarily composed of chitosan, a well-known biological material derived from crustacean shells. Chitosan’s unique chemistry, including a positive charge at physiological pH, has made it the center of much academic and clinical research (1-30). Medline’s Opticell dressings are the first application of this advanced biological material for use in chronic wound care, but chitosan has been used in other health care applications (e.g., topical hemostat, treatment of surgical wounds and traumatic injuries and in dietary supplements) because of its unique properties.

When Opticell with Chytoform technology comes into contact with moisture, it transform into a strong, absorbent and conformable gel that controls minor bleeding common in newly debrided wounds. These characteristics allow Opticell to deliver excellent outcomes.

chitosan-based

Opticell Ag+ Features

Creating An Optimal Healing Environment

  • Managing moisture to help promote autolytic debridement
  • Optimizing wound contact with a highly conformable low profile
  • Maintaining wound coverage with Surface Area Memory (SAM)

Gentle Patient Care

  • Preventing maceration by wicking fluid only vertically, not laterally
  • Reducing dressing change frequency with exceptional absorbency
  • Separating gently from the wound in one piece using advanced Cytoform technology

 

A Market Leader in Absorbency

A recent study compared Opticell’s absorptive capabilities to those of our main competitors*.

wound-skin

Helps to Prevent Maceration

Opticell’s Chytoform technology wicks fluid only vertically, not laterally. This reduces the risk of periwound maceration because wound fluid is not able to migrate across the dressing to reach this vulnerable skin.

wound-skin2

Reference

* Lab testing data on file.

Conforming to the Wound

Opticell’s conformable and thin profile provides optimal contact with the wound. Other dressings with reinforced fibers, on the other hand, may exhibit a ridging effect that can limit wound contact.

wound-skin3

References:

  1. Lord MS, Cheng B, McCarthy SJ, Jung M, Whitelock JM. The modulation of platelet adhesion and activation by chitosan through plasma and extracellular matrix proteins. Biomaterials 2011;32(28):6655-62.
  2. Rao SB, Sharma CP. Use of chitosan as a biomaterial: studies on its safety and hemostatic potential. J Biomed Mater Res 1997; 34: 21-8
  3. Ueno H, Mori T, Fujinaga T. Topical formulations and wound healing applications of chitosan. Adv Drug Deliv Rev 2001;52(2):105-15
  4. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol 2010;56(3):290-9.
  5. Chung MJ, Park JK, Park YI. Anti-inflammatory effects of low-molecular weight chitosan oligosaccharides in IgE-antigen complex-stimulated RBL-2H3 cells and asthma model mice. Int Immunophamacol. 12 (2): 453-9, 2012.
  6. Henryk Struszczyk: Alginate and Chitosan Fibers for Medical Uses. In Natural Fibers, Plastics and Composites Editors: Frederick T. Wallenberger, Norman E. Weston 2004, pp 95-104
  7. Croisier F, Jérôme C. Chitosan-based biomaterials for tissue engineering. European Polymer Journal [serial online]. April 2013;49(4):780-792.Available from: Academic Search Alumni Edition, Ipswich, MA. Accessed July 15, 2013.
  8. Madhally SV, Matthew HWT. Porous chitosan scaffolds for tissue engineering. Biomaterials 1999: 20 1333-42
  9. Roberts A, Renwick AG, Sims J, Snodin DJ. Sucralose Metabolism and Pharmacokinetics in Man. Food and Chemical Toxicology 38 (Suppl. 2) (2000)
  10. Pillai CKS, Paul W, Sharma CP. Chitin and chitosan polymers: chemistry, solubility and fiber formation. Prog Polym Sci 2009; 34: 641-78
  11. Agboh OC, Qin Y. Chitin and chitosan fibers. Polym Adv Technol 1997; 8: 355-65
  12. Zhang X, Yang D, Nie J. Chitosan/polyethylene glycol diacrylate films as potential wound dressing material. Int J Biol Macromol 2008; 43: 456-62
  13. Okamoto Y, Kawakami K, Miyatake K, Morimoto M, Shigemasa Y, Minami S. Analgesic effects of chitin and chitosan. Carbohydrate Polymers [serial online]. August 15, 2002;49(3):249-252. Available from: Academic Search Alumni Edition, Ipswich, MA. Accessed July 15, 2013.
  14. Honglue T, Rui M, Chucheng L, Ziwei L, Tingting T. Quaternized Chitosan as an Antimicrobial Agent: Antimicrobial Activity, Mechanism of Action and Biomedical Applications in Orthopedics. International Journal Of Molecular Sciences [serial online]. January 2013;14(1):1854-1869. Available from: Academic Search Alumni Edition, Ipswich, MA. Accessed July 15, 2013.
  15. Rabea, Entsa, Mohamed E.-T. Badawy, Christian V. Stevens, Guy Smagghe, and Walter Steurbaut. Chitosan as Antimicrobial Agent: Applications and Mode of Action. Biomacromolecules [serial online]. December 2003; 4(6). Available from: Academic Search Alumni Edition, Ipswich, MA. Accessed July 15, 2013.
  16. Heinze T, Koschella A. Carboxymethyl Ethers of Cellulose and Starch – A Review Macromolecular Symposia. Special Issue: Cellulose and Cellulose Derivatives Volume 223, Issue 1, pages 13–40, March 2005
  17. Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg 2010;251(2):217-28.
  18. Dowling MB, Smith W, Balogh P, Duggan MJ, MacIntire IC, Harris E, Mesar T, Raghavan SR, King DR. Hydrophobically-modified chitosan foam: description and hemostatic efficacy. J Surg Res 2015;193(1):316-23.
  19. Kulling D, Vournakis JN, Woo S, Demcheva MV, Tagge DU, Rios G, Finkielsztein S, Hawes RH. Endoscopic injection of bleeding esophageal varices with a poly-N-acetyl glucosamine gel formulation in the canine portal hypertension model. Gastrointest Endosc 1999;49(6):764-71.
  20. Huang X, Sun Y, Nie J, Lu W, Yang L, Zhang Z, Yin H, Wang Z, Hu Q. Using absorbable chitosan hemostatic sponges as a promising surgical dressing. Int J Biol Macromol 2015;75:322-9.
  21. Fischer TH, Connolly R, Thatte HS, Schwaitzberg SS. Comparison of structural and hemostatic properties of the poly-N-acetyl glucosamine Syvek Patch with products containing chitosan. Microsc Res Tech 2004;63(3):168-74.
  22. Ikeda Y, Young LH, Vournakis JN, Lefer AM. Vascular effects of poly-N-acetylglucosamine in isolated rat aortic rings. J Surg Res 2002;102(2):215-20.
  23. Chan MW, Schwaitzberg SD, Demcheva M, Vournakis J, Finkielsztein S, Connolly RJ. Comparison of poly-N-acetyl glucosamine (P-GlcNAc) with absorbable collagen (Actifoam), and fibrin sealant (Bolheal) for achieving hemostasis in a swine model of splenic hemorrhage. J Trauma 2000;48(3):454-7.
  24. Alam HB, Chen Z, Jaskille A, Querol RI, Koustova E, Inocencio R, Conran R, Seufert A, Ariaban N, Toruno K, Rhee P. Application of a zeolite hemostatic agent achieves 100% survival in a lethal model of complex groin injury in Swine. J Trauma 2004;56(5):974-83.
  25. Wedmore I, McManus JG, Pusateri AE, Holcomb JB. A special report on the chitosan-based hemostatic dressing: experience in current combat operations. J Trauma 2006;60(3):655-8.
  26. Brown MA, Daya MR, Worley JA. Experience with chitosan dressings in a civilian EMS system. J Emerg Med 2009;37(1):1-7.
  27. Tsai GJ, Su WH. Antibacterial activity of shrimp chitosan against Escherichia coli. J Food Prot 1999;62(3):239-43.
  28. Pusateri AE, McCarthy SJ, Gregory KW, Harris RA, Cardenas L, McManus AT, Goodwin CW, Jr. Effect of a chitosan-based hemostatic dressing on blood loss and survival in a model of severe venous hemorrhage and hepatic injury in swine. J Trauma 2003;54(1):177-82.
  29. Kozen BG, Kircher SJ, Henao J, Godinez FS, Johnson AS. An alternative hemostatic dressin: comparison of CELOX, HemCon, and QuikClot. Acad Emerg Med 2008;15(1):74-81.
  30. Q He et al. Positive charge of chitosan retards blood coagulation on chitosan films. J Biomaterial Applications. 27 (8): 1032-1045, May 2013.

 

Opticell Application Video:

How to Apply Opticell and Opticell Ag+ Ribbons:

VIDEOS

  • How to apply Opticell Dressings

    /catalog/includes/play-video.jsp?url=http://player.vimeo.com/video/119775579
  • Opticell Testimonial

    /catalog/includes/play-video.jsp?url=https://player.vimeo.com/video/115639043

LITERATURE

SPECIFICATIONS

SPECIFICATIONS
Brand Opticell AG+
Dressing Change Frequency/Use Max: 7 Day: Check Drainage
Dressing Type Gelling Fiber
HPIS Code 740_150_0_0
Latex Free Yes
Length Inches 18 in, 2 in, 5 in, 6 in, 12 in
Primary or Secondary Dressing Primary Dress
Product Category Silver Dressings
Sterile Yes
UNSPSC 42311504
Width Inches 0.75 in, 2 in, 5 in, 6 in, 8 in
Wound Condition Type Moderate To Heavy Drainage

SDS

Category Id: - Content Id: